Molecular targeted therapy for the treatment of renal cancer: Current state and issues

Yoshihiro Wada, Wataru Takahashi, Yoshiaki Kawano, Yutaka Sugiyama, Kenichiro Tanoue, Masatoshi Eto

Research output: Contribution to journalReview article

Abstract

In this article, we review the issues related to molecular targeted therapy for the treatment of renal cancer. In Japan, molecular targeted-based agents have been approved for use since 2008. There are two types of molecular targeted-based agents, and there are 5 targeted-based agents currently available, these being 3 vascular endothelial growth factor receptor tyrosine kinase inhibitors and 2 mammalian target of rapamycin inhibitors. Regarding the clinical use of molecular targeted agents, their positioning in metastatic renal cancer treatment is listed in Table 1. For the most part, the positioning of the agents has been determined by the results of a Phase III randomized control study (RCT). Overall survival (OS) has seldom been used as the primary end-point in contemporary phase IE RCT. Statistically significant OS has not been frequently attained in the focus study and has typically been preceded by statistically significant gains in progression-free survival (PFS). One of the greatest reasons for this is the extension of post progression survival (PPS). Increased numbers of agents have become available due to Phase IH RCT, PPS has been extended and the effects of PFS in early lines have been diluted to impact OS. In this situation, the algorithm based on such evidence from Phase IE RCT may not useful for achieving the true end-point, which is the extension of OS. Accordingly, further studies are needed to understand the role of PFS versus PPS in determining OS. The reported adverse effects (AE) of molecular targeted drugs are shown in Table 2. Molecular targeted-based agents have unique and characteristic AEs. Sequential administration is mainstream at present, however we may need to consider the AE actual usage of the agents. Conclusively, we need to integrate and develop all available knowledge in order to obtain the optimal treatment methods to extend the true end-point, which is overall survival, while maintaining the other true end-point, which is the quality of life in renal cell carcinoma patients.

Original languageEnglish
Pages (from-to)514-521
Number of pages8
JournalNishinihon Journal of Urology
Volume75
Issue number10
Publication statusPublished - Oct 2013
Externally publishedYes

Fingerprint

Molecular Targeted Therapy
Kidney Neoplasms
Survival
Disease-Free Survival
Therapeutics
TYK2 Kinase
Vascular Endothelial Growth Factor Receptor-3
Sirolimus
Renal Cell Carcinoma
Japan
Quality of Life

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Wada, Y., Takahashi, W., Kawano, Y., Sugiyama, Y., Tanoue, K., & Eto, M. (2013). Molecular targeted therapy for the treatment of renal cancer: Current state and issues. Nishinihon Journal of Urology, 75(10), 514-521.

Molecular targeted therapy for the treatment of renal cancer : Current state and issues. / Wada, Yoshihiro; Takahashi, Wataru; Kawano, Yoshiaki; Sugiyama, Yutaka; Tanoue, Kenichiro; Eto, Masatoshi.

In: Nishinihon Journal of Urology, Vol. 75, No. 10, 10.2013, p. 514-521.

Research output: Contribution to journalReview article

Wada, Y, Takahashi, W, Kawano, Y, Sugiyama, Y, Tanoue, K & Eto, M 2013, 'Molecular targeted therapy for the treatment of renal cancer: Current state and issues', Nishinihon Journal of Urology, vol. 75, no. 10, pp. 514-521.
Wada, Yoshihiro ; Takahashi, Wataru ; Kawano, Yoshiaki ; Sugiyama, Yutaka ; Tanoue, Kenichiro ; Eto, Masatoshi. / Molecular targeted therapy for the treatment of renal cancer : Current state and issues. In: Nishinihon Journal of Urology. 2013 ; Vol. 75, No. 10. pp. 514-521.
@article{e15d2cd11af54b5ebce2d554ca3186db,
title = "Molecular targeted therapy for the treatment of renal cancer: Current state and issues",
abstract = "In this article, we review the issues related to molecular targeted therapy for the treatment of renal cancer. In Japan, molecular targeted-based agents have been approved for use since 2008. There are two types of molecular targeted-based agents, and there are 5 targeted-based agents currently available, these being 3 vascular endothelial growth factor receptor tyrosine kinase inhibitors and 2 mammalian target of rapamycin inhibitors. Regarding the clinical use of molecular targeted agents, their positioning in metastatic renal cancer treatment is listed in Table 1. For the most part, the positioning of the agents has been determined by the results of a Phase III randomized control study (RCT). Overall survival (OS) has seldom been used as the primary end-point in contemporary phase IE RCT. Statistically significant OS has not been frequently attained in the focus study and has typically been preceded by statistically significant gains in progression-free survival (PFS). One of the greatest reasons for this is the extension of post progression survival (PPS). Increased numbers of agents have become available due to Phase IH RCT, PPS has been extended and the effects of PFS in early lines have been diluted to impact OS. In this situation, the algorithm based on such evidence from Phase IE RCT may not useful for achieving the true end-point, which is the extension of OS. Accordingly, further studies are needed to understand the role of PFS versus PPS in determining OS. The reported adverse effects (AE) of molecular targeted drugs are shown in Table 2. Molecular targeted-based agents have unique and characteristic AEs. Sequential administration is mainstream at present, however we may need to consider the AE actual usage of the agents. Conclusively, we need to integrate and develop all available knowledge in order to obtain the optimal treatment methods to extend the true end-point, which is overall survival, while maintaining the other true end-point, which is the quality of life in renal cell carcinoma patients.",
author = "Yoshihiro Wada and Wataru Takahashi and Yoshiaki Kawano and Yutaka Sugiyama and Kenichiro Tanoue and Masatoshi Eto",
year = "2013",
month = "10",
language = "English",
volume = "75",
pages = "514--521",
journal = "Nishinihon Journal of Urology",
issn = "0029-0726",
publisher = "Kyushu University, Faculty of Science",
number = "10",

}

TY - JOUR

T1 - Molecular targeted therapy for the treatment of renal cancer

T2 - Current state and issues

AU - Wada, Yoshihiro

AU - Takahashi, Wataru

AU - Kawano, Yoshiaki

AU - Sugiyama, Yutaka

AU - Tanoue, Kenichiro

AU - Eto, Masatoshi

PY - 2013/10

Y1 - 2013/10

N2 - In this article, we review the issues related to molecular targeted therapy for the treatment of renal cancer. In Japan, molecular targeted-based agents have been approved for use since 2008. There are two types of molecular targeted-based agents, and there are 5 targeted-based agents currently available, these being 3 vascular endothelial growth factor receptor tyrosine kinase inhibitors and 2 mammalian target of rapamycin inhibitors. Regarding the clinical use of molecular targeted agents, their positioning in metastatic renal cancer treatment is listed in Table 1. For the most part, the positioning of the agents has been determined by the results of a Phase III randomized control study (RCT). Overall survival (OS) has seldom been used as the primary end-point in contemporary phase IE RCT. Statistically significant OS has not been frequently attained in the focus study and has typically been preceded by statistically significant gains in progression-free survival (PFS). One of the greatest reasons for this is the extension of post progression survival (PPS). Increased numbers of agents have become available due to Phase IH RCT, PPS has been extended and the effects of PFS in early lines have been diluted to impact OS. In this situation, the algorithm based on such evidence from Phase IE RCT may not useful for achieving the true end-point, which is the extension of OS. Accordingly, further studies are needed to understand the role of PFS versus PPS in determining OS. The reported adverse effects (AE) of molecular targeted drugs are shown in Table 2. Molecular targeted-based agents have unique and characteristic AEs. Sequential administration is mainstream at present, however we may need to consider the AE actual usage of the agents. Conclusively, we need to integrate and develop all available knowledge in order to obtain the optimal treatment methods to extend the true end-point, which is overall survival, while maintaining the other true end-point, which is the quality of life in renal cell carcinoma patients.

AB - In this article, we review the issues related to molecular targeted therapy for the treatment of renal cancer. In Japan, molecular targeted-based agents have been approved for use since 2008. There are two types of molecular targeted-based agents, and there are 5 targeted-based agents currently available, these being 3 vascular endothelial growth factor receptor tyrosine kinase inhibitors and 2 mammalian target of rapamycin inhibitors. Regarding the clinical use of molecular targeted agents, their positioning in metastatic renal cancer treatment is listed in Table 1. For the most part, the positioning of the agents has been determined by the results of a Phase III randomized control study (RCT). Overall survival (OS) has seldom been used as the primary end-point in contemporary phase IE RCT. Statistically significant OS has not been frequently attained in the focus study and has typically been preceded by statistically significant gains in progression-free survival (PFS). One of the greatest reasons for this is the extension of post progression survival (PPS). Increased numbers of agents have become available due to Phase IH RCT, PPS has been extended and the effects of PFS in early lines have been diluted to impact OS. In this situation, the algorithm based on such evidence from Phase IE RCT may not useful for achieving the true end-point, which is the extension of OS. Accordingly, further studies are needed to understand the role of PFS versus PPS in determining OS. The reported adverse effects (AE) of molecular targeted drugs are shown in Table 2. Molecular targeted-based agents have unique and characteristic AEs. Sequential administration is mainstream at present, however we may need to consider the AE actual usage of the agents. Conclusively, we need to integrate and develop all available knowledge in order to obtain the optimal treatment methods to extend the true end-point, which is overall survival, while maintaining the other true end-point, which is the quality of life in renal cell carcinoma patients.

UR - http://www.scopus.com/inward/record.url?scp=84887422606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887422606&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:84887422606

VL - 75

SP - 514

EP - 521

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 10

ER -